Psychedelic combo trial aims to ease PTSD in veterans

NCT ID NCT06989957

Recruiting now Symptom relief Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study at Johns Hopkins is testing whether giving both psilocybin and MDMA together is safe and can help reduce PTSD symptoms in military veterans. Forty veterans with PTSD will receive the drugs in a controlled setting. The study tracks side effects, suicidal thoughts, PTSD severity, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin and MDMA
What this could lead to: If it works, this could point toward a new treatment option for PTSD that combines two psychedelic drugs.
What could go wrong: This is a very early Phase 1 trial with only 40 participants, so results may not apply widely. There are also risks like adverse events or worsening of symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTTRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTTRAUMATIC STRESS DISORDER

Contacts and locations

Locations

Johns Hopkins Center for Psychedelic and Consciousness Research
RECRUITING

Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.